NCT05510063View on ClinicalTrials.gov

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

PHASE4CompletedINTERVENTIONAL
Enrollment

371

Participants

Timeline

Start Date

August 4, 2022

Primary Completion Date

April 4, 2023

Study Completion Date

May 4, 2023

Conditions
Plaque Psoriasis
Interventions
DRUG

Humira (Adalimumab)

Subcutaneous (SC) injection

DRUG

SB5 (Adalimumab Biosimilar)

Subcutaneous (SC) injection

Trial Locations (23)

Unknown

SB Investigative Site, Dupnitsa

SB Investigative Site, Pleven

SB Investigative Site, Sofia

SB Investigative Site, Ostrava

SB Investigative Site, Pardubice

SB Investigative Site, Prague

SB Investigative Site, Kaunas

SB Investigative Site, Vilnius

SB Investigative Site, Bialystok

SB Investigative Site, Bydgoszcz

SB Investigative Site, Gdansk

SB Investigative Site, Gdynia

SB Investigative Site, Krakow

SB Investigative Site, Lodz

SB Investigative Site, Lublin

SB Investigative Site, Nowa Sól

SB Investigative Site, Olsztyn

SB Investigative Site, Osielsko

SB Investigative Site, Poznan

SB Investigative Site, Siedlce

SB Investigative Site, Szczecin

SB Investigative Site, Świdnik

SB Investigative Site, Warsaw

All Listed Sponsors
collaborator

Organon and Co

INDUSTRY

lead

Samsung Bioepis Co., Ltd.

INDUSTRY